AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 282 min read$BIIB

Biogen 3Q 2026: Revenue $2.8B, Net income ($20.6M), EPS ($0.14) — 10-Q Summary

Biogen reported 3Q 2026 revenue of $2.8B, up 10.6% YoY, with a net loss of $20.6M compared to a $466.5M profit a year earlier. Growth in rare disease and immunology products offset declines in multiple sclerosis sales. The company expects MS revenue to continue declining.

Original reporting
tradingview.com
Published Oct 28, 2026, 10:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Biogen 3Q 2026: Revenue $2.8B, Net income ($20.6M), EPS ($0.14) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$BIIBBearishHigh
01

Why it matters

The earnings miss may trigger short‑term selling pressure, but the rare‑disease pipeline offers upside potential.

02

Market read

First‑time disclosure of Biogen's Q3 2026 earnings, a material event for the stock and sector.

03

What to watch

Cost‑synergy from the recent Apellis acquisition may improve margins in future quarters.

Relevance 8/10Novelty 9/10Timing: after-hours release

Background

Biogen's Q3 2026 results were released via a 10‑Q filing, highlighting revenue growth from rare‑disease drugs and a net loss driven by multiple sclerosis sales decline.

Company-level read

Ticker impact

$BIIBBearishHigh confidence
Context

Biogen filed its Q3 2026 10‑Q reporting $2.8B revenue and a net loss of $20.6M, the first public disclosure of these results.

Expected impact

likely downside as investors price in the net loss and declining MS sales

Evidence & confidence

Revenue rose modestly but the company posted a loss and highlighted declining multiple sclerosis sales, which are a core revenue driver.

Market effects

Sector

Signals continued pressure on the neuro‑pharma segment, especially multiple sclerosis treatments.

Regional

U.S. biotech stocks may see modest pullback following the loss.

Global

Limited to investors tracking large‑cap biotech earnings.

Counterpoint

What could challenge this read

The strong growth in rare‑disease and immunology products could offset the MS decline over the longer term.

Key entities

  • company
    Biogen Inc.

    Large‑cap biotech firm reporting Q3 2026 results.

Read at source← All news

StoryBiogen posts Q3 earnings beat and lifts FY2026 non‑GAAP EPS outlook

Also covered by

6 outlets

Related articles

OCT 28
$BIIBHighAI 8/10

Biogen Slips To Loss In Q3; Raises Low-end Of FY26 Earnings View

Biogen (BIIB) reported a Q3 loss of $20.6M, down from a $466.5M profit last year, despite an 11% revenue increase to $2.8B. Adjusted EPS was $2.62, down from $4.81. The loss was driven by transaction-related charges. Biogen raised its low-end FY26 EPS outlook to $12.20-$13.00, up from $12.00-$13.00. Shares were down 0.29% in premarket trading.

rttnews.com2 min
OCT 28
$BIIBHighAI 9/10

Biogen boosts outlook after Q3 beat on multiple sclerosis franchise

Biogen (BIIB) reported Q3 2026 revenue of $2.8B, beating estimates by $170M. MS product revenue reached $919M, exceeding projections. Spinraza outperformed with $461M in sales. Syfovre and Empaveli, from the Apellis acquisition, contributed $191M and $52M respectively. Leqembi sales were $202M, slightly below consensus. Non-GAAP EPS fell 46% YoY to $2.62, but beat estimates. Biogen raised its full-year earnings outlook.

tradingview.com4 min
OCT 28
$BIIBHighAI 9/10

Biogen beats Q3 estimates, raises guidance floor on growth

Biogen Inc reported Q3 adjusted EPS of $2.62, beating estimates by $0.60, with revenue of $2.8B, up 11% YoY. Growth Portfolio revenue rose 49% YoY. The company raised its 2026 adjusted EPS guidance floor to $12.20-$13.00. Key products like SPINRAZA, LEQEMBI, and SYFOVRE showed strong sales growth. Biogen expects mid-single digit revenue growth for 2026.

finance.yahoo.com5 min
OCT 28
$BIIBHighAI 8/10

Biogen Q3 Revenue Rises 11% to $2.8 Billion; Raises EPS Guidance

Biogen reported Q3 2026 revenue of $2.8B, up 11% YoY, with non-GAAP EPS of $2.62. GAAP net loss was $20.6M due to transaction-related charges. The company raised its full-year non-GAAP EPS guidance to $12.20–$13.00. Growth was driven by its acquired Apellis products and strong performance from SPINRAZA, LEQEMBI, and SYFOVRE.

tradingview.com1 min